{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 462255885
| IUPAC_name = ''N''-[4-(5-Dimethylamino-2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)phenyl]-2-methylbenzamide
| image = Mozavaptan structure.svg

<!--Clinical data-->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status = Rx-only
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| IUPHAR_ligand = 2197
| CAS_number_Ref = {{cascite|correct|CAS}}
| CAS_number = 137975-06-5
| ATC_prefix = none
| ATC_suffix =  
| ATC_supplemental =  
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C27H29N3O2/c1-19-9-4-5-10-22(19)26(31)28-21-16-14-20(15-17-21)27(32)30-18-8-13-24(29(2)3)23-11-6-7-12-25(23)30/h4-7,9-12,14-17,24H,8,13,18H2,1-3H3,(H,28,31)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = WRNXUQJJCIZICJ-UHFFFAOYSA-N
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 420762
| PubChem = 119369
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 106618
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 17OJ42922Y

<!--Chemical data-->
| chemical_formula =  
| C=27 | H=29 | N=3 | O=2 
| molecular_weight = 427.53 g/mol
| smiles = Cc1ccccc1C(=O)Nc2ccc(cc2)C(=O)N3c4ccccc4C(CCC3)N(C)C
}}

'''Mozavaptan''' ([[International Nonproprietary Name|INN]]) is a [[vasopressin receptor antagonist]] marketed by [[Otsuka Pharmaceutical Co.|Otsuka]]. In Japan, it was approved in October 2006 for [[hyponatremia]] (low blood [[sodium]] levels) caused by [[syndrome of inappropriate antidiuretic hormone]] (SIADH) due to ADH producing tumors.

==References==
* {{cite journal
 | author = H. Spreitzer
 | date = November 20, 2006
 | title = Neue Wirkstoffe - Conivaptan
 | journal = Ã–sterreichische Apothekerzeitung
 | issue = 24/2006
 | language = German
 }}
* [https://web.archive.org/web/20120213003638/http://www.prous.com/molecules/default.asp?ID=153 Prous Science: Molecule of the Month November 2006]


{{Diuretics}}
{{Oxytocin and vasopressin receptor modulators}}

[[Category:Diuretics]]
[[Category:Hormonal agents]]
[[Category:Benzanilides]]
[[Category:Benzazepines]]
[[Category:Vasopressin receptor antagonists]]


{{antihypertensive-stub}}